Overcoming resistance to save lives
90% of mortality in cancer is attributed to drug resistance
This has been accepted as an unavoidable truth for >50 years.
resistanceBio is on a mission to understand and prevent drug resistance from the start.
Focusing on toxicity and efficacy results in drugs that work…
But resistance is what kills patients
![](https://assets-global.website-files.com/65cc6d8ae0d6826534363892/65cd08589a0de55d0f9016a1_Picture2.png)
Resistance needs time to evolve
Drugs are currently tested for 2-4 weeks
While clinical resistance takes over 3 months to evolve
![](https://assets-global.website-files.com/65cc6d8ae0d6826534363892/65cd5edbf28942a3df82591f_evolve.png)
resistanceBio combines advanced biotechnology with long-term evolution to mimic cancer resistance in humans
Remodel
Tune the environment based on known clinical outcomes
Revolution
Give cancer the time it needs
to evolve resistance
Reveal
Create a holistic map of how
resistance evolves
When we prioritize resistance
equally to toxicity and efficacy, we can...
- Develop longer-lasting drugs
- Reveal resistance pathways
- Discover novel targets
- Predict clinical outcomes
- Advance the right drug candidates
- Determine new drug superiority/inferiority
- Approve new drugs faster + cheaper
- Discover novel biomarkers
- Enroll fewer patients to reach endpoints
![](https://assets-global.website-files.com/65cc6d8ae0d6826534363892/65cc6d8ae0d6826534363988_waves-bg.png)
![](https://assets-global.website-files.com/65cc6d8ae0d6826534363892/65cc6d8ae0d6826534363958_Giovanni%20Selvaggi%2C%20MD.jpg)
"Market size for ALK in lung is around $3.5 B. Ensartinib without any additional data could be at 8-10% at peak, with resistance data could climb to 20-25%"
Giovanni Selvaggi, MD
CMO, Imugene